CHNA Loncar China BioPharma ETF
Loncar China BioPharma TR USD

NAV as of 13-May-2022

17.1371

4 Week: 15.75 - 19.93

52 Week: 15.75 - 49.00

Latest Closing Price

16.90

Premium / Discount

-2.31

Expense Ratio

0.79%

Investment Objective

The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.

Main Fund Characteristics

Fund Manager:
Loncar Investments
Asset Under Management:
5,011,305
Launch Date:
13/08/2018
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
61
Trading Currency:
USD
Style:
Large Growth
Region/Sector/Strategy:
China / N.A / N.A
Exchange:
NASDAQ

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-36.843.26-11.30
1 Day-0.650.000.00
1 Week2.218.490.26
1 Month-16.5811.99-1.38
3 Months-20.5128.61-0.72
6 Months-49.3236.76-1.34
1 Year-57.5743.62-1.32
2 Years-35.1752.01-0.68
3 Years-23.4559.73-0.39
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.00000.00000.00000.00000.000030.663134.3839-9.4178
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.000045.000048.000050.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
28/12/202130/12/20213.0314
22/12/201925/12/20190.0403

Portfolio Data

Total Number of Holdings: 61

Number of Bond Holdings: 0

Number of Equity Holdings: 59

Total Market Value: 5,011,305

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Kintor Pharmaceutical Ltd Ordinary Shares2.9705110,5000421,072
2CSPC Pharmaceutical Group Ltd2.8057342,8800397,712
3Sino Biopharmaceutical Ltd2.7866384,5000395,004
4CanSino Biologics Inc Class H2.38709,8000338,366
5BeiGene Ltd ADR2.34331,0360332,162
6Shanghai Fosun Pharmaceutical (Group) Co Ltd Class2.302378,0000326,347
7China Medical System Holdings Ltd2.2414158,0000317,717
8China Resources Pharmaceutical Group Ltd2.2033478,5000312,314
9Hansoh Pharmaceutical Group Co Ltd2.173267,5000308,051

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant5.91
Large36.62
Medium34.13
Small19.08
Micro3.94

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

12.4782

Price/Book*

1.6538

Price/Sales*

0.5236

Price/Cash Flow*

12.0562

Dividend Yield*

1.1589

Growth Measures

Long-Term Earnings

20.2519

Historical Earnings

14.7857

Sales Growth

14.1997

Cash-Flow Growth

5.2629

Book-Value Growth

14.5341

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.